<DOC>
	<DOCNO>NCT01544179</DOCNO>
	<brief_summary>The purpose study assess efficacy safety gefitinib patient progress first line gefitinib , compare continue gefitinib addition cisplatin plus pemetrexed combination chemotherapy versus cisplatin plus pemetrexed combination chemotherapy alone .</brief_summary>
	<brief_title>A Study IRESSA Treatment Beyond Progression Addition Chemotherapy Versus Chemotherapy Alone</brief_title>
	<detailed_description>A Phase III Randomised , Double blind , Placebo control , Parallel , Multicentre Study Assess Efficacy Safety continue IRESSA 250 mg addition Chemotherapy versus Chemotherapy alone Patients Epidermal Growth Factor Receptor ( EGFR ) Mutation Positive Locally advance Metastatic Non-Small Cell Lung Cancer ( NSCLC ) progress First Line IRESSA .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Male female patient age 18 year old ( For Japan male female patient age 20 year old ) Cytological histological confirmation NSCLC predominantly squamous cell histology activate EGFR TK mutation determine locally Patients document 'acquired resistance ' first line gefitinib Patients suitable start cisplatin base pemetrexed combination chemotherapy . Provision inform consent prior study specific procedure . Prior chemotherapy systemic anticancer treatment ( exclude gefitinib ) . Palliative bone radiotherapy must complete least 2 week start study treatment persistent radiation toxicity ) . Past medical history interstitial lung disease , druginduced interstitial disease , radiation pneumonitis require steroid treatment evidence clinically active interstitial lung disease Other coexist malignancy malignancy diagnose within last 5 year , exception basal cell carcinoma cervical cancer situ completely resect intramucosal gastric cancer Any evidence severe uncontrolled systemic disease Treatment investigational drug within 4 week randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Treatment Beyond Progression</keyword>
</DOC>